1.Determinants of Polycystic Ovarian Syndrome Among Adolescents with Overweight and Obesity: A Case-Control Study Protocol
Shazana Rifham Abdullah ; Nur Zati Iwani Ahmad Kamil ; Siti Sarah Hamzah ; Norhashimah Abu Seman ; Farah Huda Mohkiar ; Nur Azlin Zainal Abidin ; Ezarul Faradianna Lokman ; Azahadi Omar ; Liyana Ahmad Zamri ; Fatin Saparuddin ; Syarifah Nortasya Sayed Muhamad Kamarudin ; Puteri Sofia Nadira Megat Kamaruddin ; B. Vimala A/P R.M.T. Balasubramaniam ; Fazliana Mansor ; Nur Azurah Abdul Ghani ; Abqariyah Yahya ; Rahima Dahlan @Mohd Shafie ; Ahmad Ali Zainuddin ; Kimberly Yuin Y&rsquo ; ng Wong ; Janet Yeow Hua Hong ; Nik Sumayyah Nik Mhd Nor ; Mohd Fairulnizal Md Noh ; Muhammad Yazid Jalaludin
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):61-
Introduction:
Polycystic ovarian syndrome (PCOS) is a complex
endocrine disorder that significantly affects adolescent
girls, particularly those with overweight or obesity.
However, data examining the determinants and metabolic
profiles of PCOS among adolescents with overweight
and obesity remain limited, especially in Malaysia. This
protocol describes a case-control study investigating the
cardiometabolic, dietary, and psychosocial determinants of
PCOS among adolescents with overweight and obesity.
Methodology:
This study is designed as a case-control study involving
adolescent girls aged 13–16 years with a body mass
index z-score >+1 standard deviation. Cases are defined as adolescent girls with a confirmed diagnosis of PCOS
based on the recommendations of the 2017 International
Consortium of Paediatric Endocrinology (ICPE), while
controls are those who do not meet the diagnostic criteria
for PCOS. A total sample size of 440 participants is required.
Participants will be recruited from 22 secondary schools
selected from a list of schools in Kuala Lumpur. Data on
sociodemographic characteristics, psychosocial health,
physical activity, and dietary intake will be collected using
structured questionnaires. Blood samples will be obtained
and analyzed for diagnostic testing (free testosterone),
exclusion tests (thyroid-stimulating hormone, folliclestimulating hormone, luteinizing hormone, estradiol,
prolactin, and dehydroepiandrosterone sulfate), and
biochemical parameters (liver function tests, lipid profile,
hemoglobin A1c, fasting glucose, fasting insulin, and
inflammatory markers).
Results:
The study is expected to generate comprehensive data on
the cardiometabolic, dietary, and psychosocial determinants of PCOS among adolescents with overweight and
obesity. The findings will inform early screening strategies
and targeted interventions aimed at reducing long-term
reproductive and cardiometabolic complications.
Conclusion
This protocol outlines a structured approach to investigating PCOS in adolescence and addresses current gaps
in early identification and risk stratification among highrisk populations.
Adolescent
;
Humans
;
Case-Control Studies
;
Overweight
;
Polycystic Ovary Syndrome
;
Obesity
2.Cushing Disease Masquerading as Polycystic Ovary Syndrome: A Diagnostic Pitfall in Severe Hyperandrogenism
Jean Mun Cheah ; Fei Bing Yong ; K.J. Lingeswary ; Jen Hoong Oon ; Sharifah Noor Adrilla binti Long Mohd Noor Affendi ; Gayathri Devi A/P Krishnan ; Shazatul Reza binti Mohd Redzuan ; Subashini Rajoo Rajoo
Journal of the ASEAN Federation of Endocrine Societies 2026;41(S1):97-
Introduction:
Polycystic ovary syndrome (PCOS) is the most common
cause of hyperandrogenism in women of reproductive
age. However, several endocrine disorders, particularly
Cushing disease (CD), can closely mimic the clinical, biochemical, and radiological features of PCOS. This overlap
may lead to misdiagnosis and delayed recognition of
hypercortisolism, with significant metabolic and reproductive consequences.
Case:
We report a 24-year-old female with young-onset diabetes
mellitus who was referred for endocrine co-management
during admission for recurrent mons pubis and labial
abscesses with poorly controlled glycemia. She had a 5-year
history of progressive hirsutism, oligomenorrhoea, scalp
hair loss, significant weight gain, and insulin resistance,
and had previously been labelled as having PCOS during
adolescence, with subsequent default of follow-up. On
examination, she was obese (body mass index 33 kg/
m²) with plethoric facies, acanthosis nigricans, proximal
myopathy, and hirsutism (Ferriman–Gallwey score 10),
without overt virilization or acromegalic features.
Biochemical evaluation demonstrated severe hyperandrogenism with markedly elevated total testosterone
(7.05 nmol/L), suppressed gonadotropins, and adrenocorticotropic hormone (ACTH)-dependent hypercortisolism. Cortisol failed to suppress on low-dose dexamethasone testing, and 24-hour urinary free cortisol
was markedly elevated (>4,900 nmol/24 h). Pelvic ultrasonography and computed tomography imaging showed
polycystic ovarian morphology without evidence of an
ovarian mass. Pituitary magnetic resonance imaging
revealed a small right-sided pituitary microadenoma
measuring 2.6 × 3.7 mm. Inferior petrosal sinus sampling
demonstrated a central-to-peripheral ACTH gradient with
adequate prolactin ratios, confirming pituitary CD.
Conclusion
This case highlights how Cushing disease can closely
mimic PCOS, including polycystic ovarian morphology
and hyperandrogenism. Progressive symptoms, severe
biochemical androgen excess, and marked insulin
resistance should prompt evaluation for secondary causes
of hyperandrogenism, particularly hypercortisolism, to
avoid delayed diagnosis and prolonged morbidity.
Female
;
Hyperandrogenism
;
Pituitary ACTH Hypersecretion
;
Polycystic Ovary Syndrome
3.Extra-Ovarian Brenner Tumor of the Cervix in a 43-Year-Old Woman: A Rare Entity with Uncommon Location, Case Report
Christian Soga-ang ; Louella Tan
Philippine Journal of Pathology 2026;(75th PSP Research Competition Abstracts):1-
Introduction:
Brenner tumors are uncommon epithelial-stromal neoplasms that
usually arise in the ovary and comprise a small proportion of ovarian tumors. Extraovarian Brenner tumors are exceedingly rare, and cervical involvement is exceptional.
Because of their unusual location and histologic resemblance to other cervical epithelial
lesions, accurate diagnosis can be challenging on limited biopsy material.
Case Description:
A 43-year-old woman presented with prolonged menstrual
bleeding and a clinically suspicious cervical mass. An initial cervical punch biopsy
demonstrated benign inflammatory and metaplastic changes. Due to persistent
symptoms, a repeat biopsy was performed. Histopathologic examination revealed
well-defined nests and cords of urothelial-like epithelial cells with focal cystic change
embedded in a dense fibrous stroma. The tumor cells showed elongated nuclei
with dense chromatin, inconspicuous nucleoli, and clear cytoplasm with distinct cell
borders. Occasional mitotic figures were present without significant cytologic atypia.
Immunohistochemical studies demonstrated tumor cell positivity for GATA-3, CK7,
p63, and p16, with estrogen receptor positivity in the surrounding stroma, supporting
the diagnosis of a borderline extra-ovarian Brenner tumor of the cervix.
Discussion:
Cervical Brenner tumors are extremely rare and may closely mimic
squamous cell carcinoma, transitional cell carcinoma, or benign squamous metaplasia,
particularly in small biopsy specimens. Recognition of the characteristic nested
urothelial-like architecture, together with a focused immunohistochemical panel,
is essential for accurate classification and to prevent misdiagnosis and unnecessary
aggressive management.
Conclusion
This case highlights a rare borderline extra-ovarian Brenner tumor
arising in the cervix and emphasizes the importance of correlating histomorphologic
features with immunohistochemistry in establishing the correct diagnosis of unusual
cervical neoplasms.
Brenner Tumor
;
Immunohistochemistry
;
Urothelium
;
Uterine Cervical Neoplasms
4.Follicular Lymphoma Presenting as Bilateral Ovarian Masses, Elevated CA-125, and Lymphadenopathies: A Diagnostic Pitfall in Gynecologic Oncology
Karla Mae A. Cruzado ; Al-Zamzam A. Abubakar
Philippine Journal of Pathology 2026;(75th PSP Research Competition Abstracts):1-
Introduction:
Ovarian lymphoma is rare and often misdiagnosed, as its clinical
presentation can be similar to other more frequent tumors. It accounts for <1% of all
non-Hodgkin lymphomas, with high-grade B-cell lymphoma being the most frequently
implicated subtype.
Case Description:
A 48-year-old woman presented with bilateral ovarian masses,
elevated CA-125, and extensive abdominal and thoracic lymphadenopathy. She was
managed as advanced ovarian cancer and underwent TAHBSO. Grossly, both ovaries
were enlarged and nodular. Histology showed a round cell neoplasm composed
predominantly of medium-sized, cleaved lymphocytes, admixed with scattered larger
atypical cells. Initial immunohistochemistry panel demonstrated diffuse CD45 positivity
and negativity for AE1/AE3, Inhibin, SALL4, Desmin, and Calretinin. Subsequently,
CD20 and PAX5 showed diffuse reactivity. CD10, BCL2, and BCL6 highlighted
neoplastic follicles. CD3 was negative. High-grade B-cell lymphoma was considered;
however, the Ki-67 proliferative index was 38%, and c-MYC expression was low (5%). A
final diagnosis of follicular lymphoma involving both ovaries was rendered.
Discussion:
The clinical presentation strongly suggested advanced ovarian carcinoma.
However, histologic and immunophenotypic evaluation established lymphoma. Although
aggressive subtypes are more common in advanced cases, indolent entities such as
follicular lymphoma should also be considered, particularly in resource-limited settings
where delays in diagnosis occur. Distinguishing lymphoma from carcinoma is critical, as
management differs significantly and misclassification may lead to overtreatment.
Conclusion
Recognition of ovarian lymphoma is critical, as accurate diagnosis alters
management and prevents unnecessary radical surgery.
CA-125 Antigen
;
Immunohistochemistry
;
Lymphoma, Follicular
;
Ovarian Neoplasms
5.Emd-D inhibited ovarian cancer progression via PFKFB4-dependent glycolysis and apoptosis.
Xin ZHAO ; Chao CHEN ; Xuefei FENG ; Haoqi LEI ; Lingling QI ; Hongxia ZHANG ; Haiying XU ; Jufeng WAN ; Yan ZHANG ; Baofeng YANG
Chinese Journal of Natural Medicines (English Ed.) 2025;23(4):431-442
Ovarian cancer poses a significant threat to women's health, necessitating effective therapeutic strategies. Emd-D, an emodin derivative, demonstrates enhanced pharmaceutical properties and bioavailability. In this study, Cell Counting Kit 8 (CCK8) assays and Ki-67 staining revealed dose-dependent inhibition of cell proliferation by Emd-D. Migration and invasion experiments confirmed its inhibitory effects on OVHM cells, while flow cytometry analysis demonstrated Emd-D-induced apoptosis. Mechanistic investigations elucidated that Emd-D functions as an inhibitor by directly binding to the glycolysis-related enzyme PFKFB4. This was corroborated by alterations in intracellular lactate and pyruvate levels, as well as glucose transporter 1 (GLUT1) and hexokinase 2 (HK2) expression. PFKFB4 overexpression experiments further supported the dependence of Emd-D on PFKFB4-mediated glycolysis and SRC3/mTORC1 pathway-associated apoptosis. In vivo experiments exhibited reduced xenograft tumor sizes upon Emd-D treatment, accompanied by suppressed glycolysis and increased expression of Bax/Bcl-2 apoptotic proteins within the tumors. In conclusion, our findings demonstrate Emd-D's potential as an anti-ovarian cancer agent through inhibition of the PFKFB4-dependent glycolysis pathway and induction of apoptosis. These results provide a foundation for further exploration of Emd-D as a promising drug candidate for ovarian cancer treatment.
Female
;
Humans
;
Ovarian Neoplasms/physiopathology*
;
Phosphofructokinase-2/genetics*
;
Apoptosis/drug effects*
;
Glycolysis/drug effects*
;
Animals
;
Cell Line, Tumor
;
Mice
;
Cell Proliferation/drug effects*
;
Emodin/administration & dosage*
;
Mice, Nude
;
Mice, Inbred BALB C
;
Hexokinase/metabolism*
;
Xenograft Model Antitumor Assays
6.Molecular mechanisms of TPT1-AS1 in regulating epithelial ovarian cancer cell invasion, migration, and angiogenesis by targeting the miR-324/TWIST1 axis.
Chinese Journal of Cellular and Molecular Immunology 2025;41(6):536-543
Objective To explore the mechanism of TPT1-AS1 targeting miR-324/TWIST1 axis to regulate the proliferation, invasion, migration and angiogenesis of epithelial ovarian cancer (EOC) cells, thereby affecting ovarian cancer (OC) progression. Methods RT-qPCR was used to detect the expression of TPT1-AS1 and miR-324 in 29 OC lesions and adjacent tissue samples. The two OC cell models of TPT1-AS1 overexpression and miRNA324 knockdown were constructed, and the cell proliferation, invasion and migration abilities were detected by CCK-8, TranswellTM and scratch test. Western blot analysis was used to detect the protein expression levels of TWIST1, epithelial cadherin (E-cadherin), Vimentin, and vascular endothelial growth factor A (VEGF-A) in OC cells. Fluorescence in situ hybridization (FISH) and RNA pull-down experiments were used to verify the interaction between TPT1-AS1 and miR-324. Immunohistochemistry and Targetscan bioinformatics analysis were used to verify the negative regulatory role of miR-324 in the epithelial-mesenchymal transition (EMT) process. Results The TPT1-AS1 expression was significantly higher in OC tissues than that in para-cancerous tissues, while the miR-324 expression was significantly lower. In SKOV3 cells with TPT1-AS1 overexpression, the miR-324 expression decreased significantly, and TPT1-AS1 was negatively correlated with miR-324. It was also found that TPT1-AS1 and miR-324 were co-expressed in OC cells, and there was a direct binding relationship between them. Down-regulation of miR-324 significantly promoted the proliferation, invasion and migration of SKOV3 cells. Further studies revealed that miR-324 had a binding site at the 3'-UTR end of the TWIST1, a key transcription factor for EMT. Inhibiting miR-324 expression increased the transcription level of TWIST1, leading to a decrease in E-cadherin protein expression and an increase in Vimentin protein expression. Additionally, the downregulation of miR-324 resulted in an increased expression level of VEGF-A protein, which in turn enhanced angiogenesis of OC. Conclusion TPT1-AS1 promotes EOC cell proliferation, invasion, migration and angiogenesis by negatively regulating the miR-324/TWIST1 axis, thus promoting the development of OC. These findings provide new potential targets for the diagnosis and treatment of OC.
Humans
;
MicroRNAs/metabolism*
;
Female
;
Cell Movement/genetics*
;
Ovarian Neoplasms/blood supply*
;
Twist-Related Protein 1/metabolism*
;
Cell Line, Tumor
;
Neovascularization, Pathologic/genetics*
;
Neoplasm Invasiveness
;
Carcinoma, Ovarian Epithelial/metabolism*
;
Nuclear Proteins/metabolism*
;
Cell Proliferation/genetics*
;
Epithelial-Mesenchymal Transition/genetics*
;
Gene Expression Regulation, Neoplastic
;
RNA, Long Noncoding/metabolism*
;
Cadherins/genetics*
;
Vascular Endothelial Growth Factor A/genetics*
;
Vimentin/genetics*
;
Angiogenesis
7.Primary Non-Hodgkin Lymphoma in the Female Genital System: Report of Two Cases and Review of the Literature.
Tian-Yu ZHANG ; Li QIN ; Dong-Yan CAO ; Jia-Xin YANG ; Yi LIU ; Tao WANG
Acta Academiae Medicinae Sinicae 2025;47(2):314-318
Primary female genital system lymphoma(PFGSL)is a rare subtype of extranodal lymphoma and patients commonly present in the department of gynecology.At present,there is a lack of uniform standards for the treatment of PFGSL.Although the classification of lymphoid neoplasmas was updated by the World Health Organization classification of haematolymphoid tumors in 2016,PFGSL was still not elaborated in sufficient detail.Most cases of PFGSL are non-Hodgkin lymphoma,involving the ovary and cervix.In some cases,involvement of uterine corpus,vagina,and vulva is reported.In this article,we report two cases of non-Hodgkin lymphoma in the female genital system,one from the uterus and the other from the ovary.By presenting the diagnosis and treatment of the two cases and reviewing the literature,we aim to provide a reference for clinicians in recognizing and treating rare cases.
Female
;
Humans
;
Genital Neoplasms, Female/diagnosis*
;
Lymphoma, Non-Hodgkin/diagnosis*
;
Ovarian Neoplasms
8.Effect of the Small Molecule Inhibitor of Kallikrein-Related Peptidase 7 Against Ovarian CancerA.
Hong-Juan SHI ; Wei LIU ; Li-Ling HU ; Xiao TAN
Acta Academiae Medicinae Sinicae 2025;47(3):366-374
Objective To investigate the effect of the small molecule inhibitor C42 of kallikrein-related peptidase 7(KLK7)on ovarian cancer with elevated expression of KLK7 and evaluate the feasibility of C42 as a new therapeutic strategy for ovarian cancer.Methods The CCK-8 assay,flow cytometry,cell scratch assay,Transwell assay,and Western blotting were employed to assess the effects of C42 on the proliferation,migration,and invasion of the ovarian cancer cell line SKOV3,which was characterized by high KLK7 expression.Additionally,a subcutaneous xenograft model of ovarian cancer was established with SKOV3 cells in nude mice to evaluate the effects of C42 on the tumor growth and metastasis.The expression levels of proteins associated with tumor metastasis and invasion in the tumor tissue were examined by immunohistochemical techniques.Results The cellular experiment showed that C42 suppressed the proliferation,migration,and invasion(all P<0.001)of SKOV3 cells,compared with the control group.The animal experiment showed that compared with the control group,the 10.2 mg/kg C42 group exhibited a decreased tumor weight(P=0.009) and attenuated liver metastases.Immunohistochemical staining revealed that the 10.2 mg/kg C42 group demonstrated down-regulated expression of the tumor proliferation marker Ki-67(P=0.002)and the tumor metastasis and invasion-associated proteins such as matrix metalloproteinase-9(P=0.027)and Vimentin(P=0.039).Conclusion The small molecule inhibitor C42 of KLK7 effectively suppresses the proliferation,migration,and invasion of ovarian cancer SKOV3 cells.
Female
;
Humans
;
Ovarian Neoplasms/drug therapy*
;
Kallikreins/antagonists & inhibitors*
;
Animals
;
Mice, Nude
;
Cell Line, Tumor
;
Cell Proliferation/drug effects*
;
Mice
;
Cell Movement/drug effects*
;
Xenograft Model Antitumor Assays
;
Mice, Inbred BALB C
9.Ovarian malignancy in a patient with Herlyn–Werner–Wunderlich syndrome: A rare clinical presentation
Gilana Abinales Gonzales ; Aubrey Y. Señ ; eris
Philippine Journal of Obstetrics and Gynecology 2025;49(4):258-262
Herlyn–Werner–Wunderlich Syndrome (HWWS) is a rare congenital Mullerian duct anomaly, characterized by the presence of an obstructed hemivagina with uterus didelphys and an ipsilateral renal anomaly (OHVIRA). Ovarian serous adenocarcinoma is a type of epithelial ovarian cancer and accounts for about 90% of all ovarian cancers. The incidence of Müllerian duct anomalies associated with ovarian cancer is unknown. Due to its rarity of these conditions, diagnosis and management are challenging. In this paper, we present a case of a 53-year-old, nulligravid woman who presented with an acute abdomen. A transrectal and transabdominal sonography showed an ovarian mass with malignant features. Immediate surgical intervention was performed, and removal of the ovarian mass was done. Intraoperatively, findings of obstructed hemivagina, uterine didelphys, and the absence of one kidney were noted, suggestive of HWWS. Biopsy of the mass revealed borderline serous cystadenocarcinoma of the right ovary.
Human ; Ovarian Neoplasms
10.Electroacupuncture Improves Pregnancy Outcomes of Assisted Reproduction and Mitochondrial Function of Granulosa Cells in Patients with Polycystic Ovary Syndrome of Phlegm-Dampness Syndrome.
Cong-Hui PANG ; Dan-Yang GUO ; Qi WANG ; Ke-Hua WANG ; Fang LIAN
Chinese journal of integrative medicine 2025;31(12):1105-1112
OBJECTIVE:
To explore the effects of electroacupuncture (EA) on pregnancy outcomes after assisted reproduction and mitochondrial function of granulosa cells (GCs) in patients with polycystic ovary syndrome (PCOS) and phlegm-dampness syndrome.
METHODS:
In this randomized controlled trial, 90 infertile women with PCOS and phlegm-dampness syndrome were recruited between August 2022 and December 2022. Patients were randomly assigned to the EA and control groups using a random sequence of codes in the order of enrolment, with 45 in in each group. Both groups underwent the ovarian stimulation protocol. The patients in the EA group received EA therapy including Zhongwan (CV 12), Qihai (CV 6), bilateral Xuehai (SP 10), Sanyinjiao (SP 6), Yinlingquan (SP 9), Tianshu (ST 25), Zusanli (ST 36), and Fenglong (ST 40), and the patients in the control group was treated with pseudo-acupuncture. The intervention was 25 min twice a week for a total of 6 times until the trigger day after menstruation had ended in the cycle before oocyte retrieval. The primary outcomes were clinical pregnancy rate (CPR) and the number of high-quality embryos. The secondary outcomes were (1) pregnancy-related indicators, including fresh embryo transfer rate (ETR), ovarian hyperstimulation syndrome (OHSS) rate, early pregnancy loss rate (ePLR), ectopic pregnancy rate, live birth rate (LBR), and cumulative CPR; (2) mitochondrial autophagy and mitochondrial membrane potential (MMP) in GCs; and (3) scoring for Chinese medicine syndrome. Adverse events to assess clinical safety were also monitored.
RESULTS:
The cumulative CPR was significantly higher in the EA group (42/45, 93.3%) than in the control group (38/45, 84.4%, P=0.036). The number of high-quality embryos and fresh ETR in the EA group were higher than those in the control group (3.80±1.65 vs. 2.44±1.34, P<0.001; 46.7% vs 24.4%, P=0.028). Ectopic pregnancies were not observed in either group. There were no significant differences in the fresh CPR, OHSS rate, ePLR or LBR between the two groups (P>0.05). Compared with the control group, the EA group showed lower expression levels of miR-146a-5p mRNA and P62 protein in GCs and higher levels of MMP and the LC3-II/LC3-I protein ratio (all P<0.01). The phlegm-dampness syndrome scores of the EA group were significantly lower than those of the control group (P<0.01).
CONCLUSIONS
EA significantly improved pregnancy outcomes in patients with PCOS and phlegm dampness syndrome. Mechanistically, this effect may be related to EA in decreasing miR-146a-5p mRNA expression, promoting mitochondrial autophagy in GCs, and improving mitochondrial function, which may contribute to improved oocyte quality. (Trial registration No. ChiCTR2200062915).
Humans
;
Female
;
Polycystic Ovary Syndrome/therapy*
;
Pregnancy
;
Electroacupuncture
;
Granulosa Cells/metabolism*
;
Adult
;
Mitochondria/metabolism*
;
Pregnancy Outcome
;
Pregnancy Rate
;
Reproductive Techniques, Assisted
;
Infertility, Female/therapy*


Result Analysis
Print
Save
E-mail